These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 11057860)

  • 1. Sequence alignment between vWF and peptides inhibiting the vWF-collagen interaction does not result in the identification of a collagen-binding site in vWF.
    Vanhoorelbeke K; van der Plas RM; Vandecasteele G; Vauterin S; Huizinga EG; Sixma JJ; Deckmyn H
    Thromb Haemost; 2000 Oct; 84(4):621-5. PubMed ID: 11057860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A3 domain is essential for interaction of von Willebrand factor with collagen type III.
    Lankhof H; van Hoeij M; Schiphorst ME; Bracke M; Wu YP; Ijsseldijk MJ; Vink T; de Groot PG; Sixma JJ
    Thromb Haemost; 1996 Jun; 75(6):950-8. PubMed ID: 8822592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of von Willebrand factor to collagen type III: role of specific amino acids in the collagen binding domain of vWF and effects of neighboring domains.
    van der Plas RM; Gomes L; Marquart JA; Vink T; Meijers JC; de Groot PG; Sixma JJ; Huizinga EG
    Thromb Haemost; 2000 Dec; 84(6):1005-11. PubMed ID: 11154106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.
    Ribba AS; Loisel I; Lavergne JM; Juhan-Vague I; Obert B; Cherel G; Meyer D; Girma JP
    Thromb Haemost; 2001 Sep; 86(3):848-54. PubMed ID: 11583318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of peptides, selected by phage display technology, that inhibit von Willebrand factor binding to collagen.
    Depraetere H; Viaene A; Deroo S; Vauterin S; Deckmyn H
    Blood; 1998 Dec; 92(11):4207-11. PubMed ID: 9834225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental indication for the existence of multiple Trp rotamers in von Willebrand Factor A3 domain.
    Hellings M; Engelborghs Y; Deckmyn H; Vanhoorelbeke K; Schiphorst ME; Akkerman JW; De Maeyer M
    Proteins; 2004 Nov; 57(3):596-601. PubMed ID: 15382239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and alpha2beta1(GPIa/IIa)-I-domain binding to collagen in a different manner.
    Depraetere H; Kerekes A; Deckmyn H
    Thromb Haemost; 1999 Sep; 82(3):1160-3. PubMed ID: 10494781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characterization and functional studies of vWF A3 domain monoclonal antibodies that inhibit binding of vWF to collagen].
    Zhao YM; Dong NZ; Shen F; Xie LQ; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):171-4. PubMed ID: 18788616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction.
    Vanhoorelbeke K; Depraetere H; Romijn RA; Huizinga EG; De Maeyer M; Deckmyn H
    J Biol Chem; 2003 Sep; 278(39):37815-21. PubMed ID: 12855711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of von Willebrand factor (vWf) with collagen: investigation of vWf-binding sites in the collagen molecule.
    Fitzsimmons CM; Cockburn CG; Hornsey V; Prowse CV; Barnes MJ
    Thromb Haemost; 1988 Apr; 59(2):186-92. PubMed ID: 3260414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation.
    Benard SA; Smith TM; Cunningham K; Jacob J; DeSilva T; Lin L; Shaw GD; Kriz R; Kelleher KS
    Biochemistry; 2008 Apr; 47(16):4674-82. PubMed ID: 18363340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
    Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
    Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of phages that inhibit vWF interaction with collagen under both static and flow conditions.
    Ulrichts H; Depraetere H; Harsfalvi J; Deckmyn H
    Thromb Haemost; 2001 Aug; 86(2):630-5. PubMed ID: 11522014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collagen-binding mode of vWF-A3 domain determined by a transferred cross-saturation experiment.
    Nishida N; Sumikawa H; Sakakura M; Shimba N; Takahashi H; Terasawa H; Suzuki E; Shimada I
    Nat Struct Biol; 2003 Jan; 10(1):53-8. PubMed ID: 12447349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Thr789Ala variant of the von Willebrand factor levels, on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2.
    Klemm T; Mehnert AK; Siegemund A; Wiesner TD; Gelbrich G; Blüher M; Paschke R
    Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):568-72. PubMed ID: 16320153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of antibodies that interfere with the collagen-VWF-GPIb axis as new antithrombotics.
    Deckmyn H; Cauwenberghs N; Wu D; Depraetere H; Vanhoorelbeke K
    Verh K Acad Geneeskd Belg; 2005; 67(1):55-65. PubMed ID: 15828307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs.
    Sabino EP; Erb HN; Catalfamo JL
    Am J Vet Res; 2006 Feb; 67(2):242-9. PubMed ID: 16454628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
    Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
    Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.